STO · EGTX.ST
Egetis Therapeutics AB (publ)
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
Loading market information…
STO · DMYD-B.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Diamyd Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Diamyd Medical AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:23 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
SEK 21.80-SEK 0.20 (-0.91%)
Genovis AB’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 68.30+SEK 0.40 (+0.59%)
Infant Bacterial Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
SEK 1.71+SEK 0.05 (+3.07%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
SEK 10.70+SEK 0.22 (+2.1%)
Xspray Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 70.4% below the high.
SEK 1.67+SEK 0.20 (+13.2%)
Cantargia AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
